EIR Biopharma, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-02-17. As of its latest filing, on 2026-02-17, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We intend to apply to list our common stock on the New York Stock Exchange, or NYSE, American under the symbol “____”.From the S-1 filed 2026-02-17
Price range
It is currently estimated that the initial public offering price will be between $4.00 and $5.00 per share.From the S-1 filed 2026-02-17
Use of proceeds
We intend to use the net proceeds from this offering to fund the preclinical and clinical development of EIR-1003, research activities, working capital and general corporate purposes.From the S-1 filed 2026-02-17
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-02-17 | Registration statement filed | S-1 |
Tools for this story
Each opens in a new tab, filled in for EIR Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.